Loading...
Docoh

Codiak Biosciences (CDAK)

News

From Benzinga Pro
Stocks That Hit 52-Week Lows On Friday
6 May 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Friday, 1043 companies hit new 52-week lows.
Codiak BioSciences Q1 Sales $12.70M Down From $13.19M YoY
5 May 22
Earnings, News
Codiak BioSciences (NASDAQ:CDAK) reported $12.70 million in sales this quarter. This is a 3.72 percent decrease over sales of $13.19 million the same period last year.
Stocks That Hit 52-Week Lows On Thursday
28 Apr 22
News, Options, Intraday Update, Markets
During Thursday, 849 stocks hit new 52-week lows.
Stocks That Hit 52-Week Lows On Friday
22 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Friday, 431 companies hit new 52-week lows.
Stocks That Hit 52-Week Lows On Thursday
21 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Thursday, 236 companies hit new 52-week lows.
The Daily Biotech Pulse: Ampio Falls On Knee Osteoarthritis Trial Update, AstraZeneca's COVID-19 Antibody Data, CureVac-GSK's Bivalent COVID-19 Vaccine Data
21 Apr 22
Biotech, News, Penny Stocks, Health Care, Small Cap, FDA, Management, Movers, Trading Ideas, General
Here's a roundup of top developments in the biotech space over the last 24 hours.
Codiak BioSciences's Pan Beta-Coronavirus Vaccine Shows Encouraging Action In Animal Studies
21 Apr 22
Biotech, News, Penny Stocks, Health Care, General
Codiak Presents New Preclinical Data Supporting Development Of A Broadly Protective Pan Beta-Coronavirus Vaccine
20 Apr 22
Biotech, News, FDA, General
Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based candidates as a new class of medicines, today announced new preclinical data from
Stocks That Hit 52-Week Lows On Wednesday
20 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Wednesday, 160 companies hit new 52-week lows.
Stocks That Hit 52-Week Lows On Monday
18 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Monday, 466 companies hit new 52-week lows.
Codiak BioSciences' Precision Medicine Approach Shows Potent Activity In Cancer Models
11 Apr 22
Biotech, News, Health Care, General
Codiak BioSciences Inc (NASDAQ: CDAK)
Looking Into Codiak BioSciences's Return On Capital Employed
15 Mar 22
Earnings
According to Benzinga Pro, during Q4, Codiak BioSciences (NASDAQ:CDAK) earned $16.66 million, a 176.78% increase from the preceding quarter. Codiak BioSciences also posted a total of $7.70 million in sales, a 565.25% increase since Q3.
Codiak BioSciences Q4 EPS $0.74 Up From $(1.14) YoY, Sales $7.70M Up From $1.64M YoY
10 Mar 22
Earnings, News
Codiak BioSciences (NASDAQ:CDAK) reported quarterly earnings of $0.74 per share. This is a 164.91 percent increase over losses of $(1.14) per share from the same period last year. The company reported $7.70 million in
Stocks That Hit 52-Week Lows On Tuesday
22 Feb 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
During Tuesday's trading, 505 companies set new 52-week lows.
Wedbush Maintains Outperform on Codiak BioSciences, Lowers Price Target to $24
22 Feb 22
News, Price Target, Analyst Ratings
Wedbush analyst David Nierengarten maintains Codiak BioSciences (NASDAQ:CDAK) with a Outperform and lowers the price target from $34 to $24.

Press releases

From Benzinga Pro
Codiak BioSciences Reports First Quarter 2022 Financial Results and Operational Progress
5 May 22
Earnings, Press Releases
– Codiak to provide data from ongoing exoSTING™ and exoIL-12™ clinical trials in late 1H 2022 – – Anticipate first patients dosed in exoASO™-STAT6 Phase 1 clinical trial in 1H 2022 – – Data from
Codiak Presents New Preclinical Data Supporting Development of a Broadly Protective Pan Beta-Coronavirus Vaccine
20 Apr 22
Health Care, Press Releases, General
– Engineered exosome vaccine construct generated durable, comprehensive immunity in vivo – CAMBRIDGE, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage
Tessera Therapeutics Announces Over $300M Series C Financing to Advance its GENE WRITING Platform
19 Apr 22
Penny Stocks, Small Cap, Press Releases
Latest Financing Round Will Support Tessera's Build Out of its GENE WRITING Platforms and Pursuit of Multiple Therapeutic Programs for Clinical Development
Flagship Pioneering Bolsters Executive Team with Appointment of Michelle C. Werner as CEO-Partner and CEO of Alltrna
11 Apr 22
Press Releases
Werner Brings More Than Two Decades of Pharmaceutical Leadership to the Role CAMBRIDGE, Mass., April 11, 2022 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced it has strengthened
Codiak BioSciences Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Progress
10 Mar 22
Earnings, News, Press Releases
– Reported positive initial data from exoSTING™ clinical trial; on track to provide data from all dose escalation cohorts in late 1H 2022 – – Investigational New Drug (IND) application cleared for
Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs
28 Feb 22
Small Cap, Press Releases
CAMBRIDGE, Mass., Feb.